(Q33493801)

27 July 2017

title

EPIC: an effective low toxicity regimen for relapsing lymphoma (English)

1 reference

27 July 2017

3

Cunningham D

1 reference

27 July 2017

8

Catovsky D

1 reference

27 July 2017

Hickish T

1

1 reference

27 July 2017

Roldan A

2

1 reference

27 July 2017

Mansi J

4

1 reference

27 July 2017

Ashley S

5

1 reference

27 July 2017

Nicolson V

6

1 reference

27 July 2017

Gore ME

7

1 reference

27 July 2017

Smith IE

9

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 September 1993

1 reference

British Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

68

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

599-604

1 reference

Reporting results of cancer treatment

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Ifosfamide in experimental tumor systems

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Peripheral sensory neuropathy and cisplatin chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Preclinical studies and clinical correlation of the effect of alkylating dose.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

The role of chemotherapy in diffuse aggressive lymphomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Phase I study of continuous-infusion cisplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Hodgkin's disease: the role of bone marrow transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

The use of chemotherapy in the treatment of Hodgkin's disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Mechanism of action of cis-dichlorodiammineplatinum(II)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968387

Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity

31 October 2018

1 reference

12 December 2020

Ifosfamide--current aspects and perspectives

1 reference

12 December 2020

High-Dose Cisplatin in Hypertonic Saline

1 reference

12 December 2020

Histologic conversion in the non-Hodgkin's lymphomas

1 reference

12 December 2020

Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity

1 reference

12 December 2020

Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations

1 reference

12 December 2020

Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen

1 reference

12 December 2020

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

1 reference

12 December 2020

Results of MIME salvage regimen for recurrent or refractory lymphoma

1 reference

12 December 2020

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

12 December 2020

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

1 reference

12 December 2020

Interaction of etoposide and cisplatin in an in vitro tumor model

1 reference

12 December 2020

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of

1 reference

12 December 2020

Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma

1 reference

12 December 2020

Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease

1 reference

12 December 2020

A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors

1 reference

12 December 2020

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

12 December 2020

Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation

1 reference

12 December 2020

Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study

1 reference

12 December 2020

PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)

1 reference

12 December 2020

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

12 December 2020

Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II)

1 reference

12 December 2020

Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma

1 reference

12 December 2020

Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant

1 reference

12 December 2020

IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy

1 reference

12 December 2020

Etoposide--chemistry, preclinical and clinical pharmacology

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1993.393

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference